ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Antimalarial drugs"

  • Abstract Number: 2569 • 2019 ACR/ARP Annual Meeting

    Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review

    Gemma Cramarossa1, Janet Pope 2 and Matthew Turk 3, 1Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada, 2Western University, London, ON, Canada, 3University of Western Ontario, London, ON, Canada

    Background/Purpose: The purpose of this systematic review was to identify existing guidelines for antimalarial prescribing and monitoring in rheumatic diseases, specifically for hydroxychloroquine, and how…
  • Abstract Number: 2897 • 2019 ACR/ARP Annual Meeting

    Increased CD69+ Tissue-resident Memory T (TRM) Cells and STAT3 Expression in Cutaneous Lupus Erythematosus Patients Recalcitrant to Antimalarials

    Majid Zeidi 1, Kristen Chen 1, Krisha Desai 1, Hee Joo Kim 2, Srita Chakka 3, Rachel Lim 4 and Victoria Werth1, 1Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 2Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA andDepartment of Dermatology, University of Pennsylvania, Philadelphia, PA, USA and Department of Dermatology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea, Republic of (South), Philadelphia, 3Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, 4Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA, Philadelphia

    Background/Purpose: Cutaneous lupus erythematosus (CLE) is an autoimmune disease with various subsets and clinical manifestations. T lymphocytes are the predominant cell type found in lesional…
  • Abstract Number: 2526 • 2019 ACR/ARP Annual Meeting

    Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus

    Ioannis Parodis1, Sofia Soukka 1, Alvaro Gomez 1, Yvonne Enman 1, Petter Johansson 1, Sharzad Emamikia 1 and Katerina Chatzidionysiou 1, 1Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) suffer an impaired health-related quality of life (HRQoL), and the majority of them experience fatigue as a major…
  • Abstract Number: 105 • 2018 ACR/ARHP Annual Meeting

    Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials

    Majid Zeidi1,2, Krisha Desai3,4, Hee Joo Kim3,4,5 and Victoria P. Werth3,4, 1University of Pennsylvania, Philadelphia, PA, 2Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, 3Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, 4Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5Department of Dermatology, Gachon Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea, Republic of (South)

    Background/Purpose: Two major therapies for cutaneous lupus erythematosus (CLE) are the antimalarials, hydroxychloroquine (HCQ) and quinacrine (QC). HCQ is often the first-line therapy for CLE,…
  • Abstract Number: 496 • 2018 ACR/ARHP Annual Meeting

    Heart Failure Risk Among Patients with Rheumatoid Arthritis: Association with Anti-Rheumatic Drugs

    Michael Ahlers1, C. Michael Stein2, Cecilia P. Chung2, Michelle J. Ormseth3, Eric Farber-Eger3 and Deepak Gupta4, 14906 illinois avenue, Vanderbilt University School of Medicine, Nashville, TN, 2Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 3Vanderbilt University Medical Center, Nashville, TN, 4Internal Medicine - Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of coronary artery disease (CAD), but the association with heart failure (HF) is less characterized.  We…
  • Abstract Number: 2646 • 2018 ACR/ARHP Annual Meeting

    Disparities in Antimalarial Prescribing for Systemic Lupus Erythematous Nephritis Using a Real-World, Electronic Health Record

    Wenlu Xiong1, J.B. Boone1, Cecilia P. Chung1, Leslie Crofford2 and April Barnado2, 1Medicine, Vanderbilt University Medical Center, Nashville, TN, 2Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Antimalarials (AMs) improve survival in patients with systemic lupus erythematosus (SLE). Current guidelines suggest AMs for all SLE nephritis patients. Studies using patient-reported data…
  • Abstract Number: 714 • 2017 ACR/ARHP Annual Meeting

    Prolonged Antimalarial Treatment Is Associated with Increased Risk for Elevated Myocardial Biomarkers in Systemic Lupus Erythematosus

    Konstantinos Tselios1, Dafna D Gladman2, Paula Harvey3, Shadi Akhtari3, Jiandong Su4 and Murray Urowitz2, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Antimalarial (AM)-induced cardiomyopathy (AMIC) has been rarely reported in systemic lupus erythematosus (SLE). However, given the large number of patients treated, it seems possible…
  • Abstract Number: 2599 • 2017 ACR/ARHP Annual Meeting

    Efficacy and Toxicity of Antimalarials in Systematic Lupus Erythematosus: A Systematic Review

    Gaurav Sharma1, Jasvinder A. Singh2, Mohammed Sohaib Khaleel3 and Shristi Shrestha4, 1Department of Medicine, Division of Immunology and Rheumatology, UAB School of Medicine, Birmingham, AL, 2Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Department of Molecular Cardiology, University of Louisville, Louisville, KY, 4Internal Medicine, Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal

    Background/Purpose: To determine the efficacy and adverse effects of antimalarials in patients with systematic lupus erythematosus (SLE). Methods: A literature search from inception to December…
  • Abstract Number: 2613 • 2017 ACR/ARHP Annual Meeting

    Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients

    Lavanya Mittal1, Lingqiao Zhang2, Rui Feng2 and Victoria Werth1, 1Department of Dermatology, Corporal Michael J. Crescenz VAMC, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remain debated. Quinacrine may…
  • Abstract Number: 2984 • 2016 ACR/ARHP Annual Meeting

    Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation through Inhibition of CGAS-Sting Pathway in Trex1-/- Mouse

    Jie An1, Joshua Woodward2, Mark Minie3, Xizhang Sun4, Lena Tanaka1, Yufeng Peng1, Jessica Snyder4, Tomikazu Sasaki5 and Keith B. Elkon6, 1Division of Rheumatology, University of Washington, Seattle, WA, 2Department of Microbiology, University of Washington, Seattle, WA, 3Department of Bioengineering, University of Washington, Seattle, WA, 4University of Washington, Seattle, WA, 5Department of Chemistry, University of Washington, Seattle, WA, 6Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: Type I interferon, (IFN-I) is strongly implicated in the pathogenesis of SLE as well as rare monogenic ‘interferonopathies’ such as Aicardi-Goutieres Syndrome (AGS) caused…
  • Abstract Number: 1813 • 2015 ACR/ARHP Annual Meeting

    Novel Mechanism of Action of Anti-Malarial Drugs in the Inhibition of Type I Interferon Production

    Jie An1, Joshua Woodward2, Mark Minie3, YuFeng Peng4, Tomikazu Sasaki5 and Keith B. Elkon6, 1Division of Rheumatology, Department of Medicine & Immunology, University of Washington, Seattle, WA, 2Department of Microbiology, University of Washington, Seattle, WA, 3Department of Bioengineering, University of Washington, Seattle, WA, 4Rheumatology, University of Washington, Seattle, WA, 5Department of Chemistry, University of Washington, Seattle, WA, 6Department of Medicine & Immunology, University of Washington, Seattle, WA

    Background/Purpose: Anti-malarial drugs (AMD) such as Hydroxychloroquine (HCQ) and Quinacrine (QC) are effective in the treatment of skin rash and arthritis in systemic lupus erythematosus…
  • Abstract Number: 680 • 2014 ACR/ARHP Annual Meeting

    Influence of Antimalarial doesn´t Modify the Outcome of Cytopenias in Systemic Lupus Erythematosus

    Eugenia Enriquez Merayo1, Maria Galindo Izquierdo2, Esther Rodriguez-Almaraz3, Maria Martin Lopez2, Otto Martin Olivas Vergara4, Patricia E. Carreira5 and Isabel Mateo6, 1RHEUMATOLOGY, 12 DE OCTUBRE, MADRID, Spain, 2RHEUMATOLOGY, HOSPITAL 12 DE OCTUBRE, MADRID, Spain, 3Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, 4HOSPITAL 12 DE OCTUBRE, MADRID, Spain, 5Rheumatology Department. Hospital Universitario 12 de Octubre, Madrid, Spain, 6Servicio De Reumatología, Hospital 12 De Octubre,, Madrid, Spain

    Background/Purpose: To analyze the effect of antimalarials (AM) as preventive factor for the development of severe cytopenias and in their outcome after treatment in a…
  • Abstract Number: 2832 • 2013 ACR/ARHP Annual Meeting

    The Effect Of Maternal Antimalarial Intake During Pregnancy On The Risk Of Neonatal Lupus

    Julie Barsalou1, Edgar Jaeggi2 and Earl D. Silverman1, 1Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 2Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Neonatal Lupus (NLE) results from passive transfer of anti-Ro and/or anti-La antibodies to the fetus during gestation. It has been suggested that prenatal exposure…
  • Abstract Number: 1613 • 2013 ACR/ARHP Annual Meeting

    Anti-Malarial Drugs (hydroxychloroquine and quinacrine) Decrease The Production Of Interferon-Alfa Initiated By TLR-9 Agonist

    Ou Jin1, Xi Zhang1, Qiuxia Li1, Lingkai Fang1, Hongyue Huang1, Chengcheng Hou1, Zetao Liao1, Qiujing Wei1, Zhiming Lin2, Dongfang Lin1 and Jieruo Gu3, 1Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, 2Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, 3Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China

    Background/Purpose: Toll-like receptor 9 (TLR-9) plays an important role in initiating innate immunity.  The recognition of self DNA fragments by TLR-9 may results in the…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology